Abstract
Intellectual property right (IPR) negotiations during the Uruguay Round (UR) negotiations were characterized by significant disagreement between developed and developing countries. For developing countries, the WTO system might have gone too far on patents. It is particularly true for essential medicines critical to human life and health. The Agreement on Trade-related Aspects of Intellectual Property Rights (TRIPS) of the WTO includes a few provisions on special and differential treatment (SDT) of developing countries. However, these do not specifically mention pharmaceutical products. Patentability of pharmaceutical products may be analysed in light of fairness. From the viewpoint of distributional fairness, this article derives several policy suggestions for pharmaceutical products in fair international economic relations.
| Original language | English |
|---|---|
| Pages (from-to) | 249-268 |
| Number of pages | 20 |
| Journal | Perspectives on Global Development and Technology |
| Volume | 18 |
| Issue number | 3 |
| DOIs | |
| State | Published - 2019 |
Bibliographical note
Publisher Copyright:© 2019 by Koninklijke Brill NV, Leiden, The Netherlands.
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Keywords
- WTO
- distributional fairness
- patents
- pharmaceutical products
Fingerprint
Dive into the research topics of 'Patents on Pharmaceutical Products in Fair International Economic Relations'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver